ERBB3 and neoplasm: Based on the results of the present study, the measurement of serum ERBB3 appeared unsuitable for the surveillance of patients with cirrhosis for the risk of HCC development; indeed, the biomarker was not able to discriminate between patients with cirrhosis and those with early tumor.